CRDF
Cardiff Oncology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CRDF Profile
Cardiff Oncology, Inc.
A clinical-stage biotechnology company that develops novel therapies for a range of cancers
Biological Technology
04/26/2002
05/29/2012
NASDAQ Stock Exchange
33
12-31
Common stock
11055 Flintkote Avenue, San Diego, California 92121
--
Cardiff Oncology, Inc., was incorporated in Florida on April 26, 2002. The company is a clinical-stage biotechnology company that utilizes PLK1 inhibition, a well-proven oncology drug target, to develop new therapies across a range of unmet medical needs for cancer. The company aims to target tumor vulnerability through a therapeutic combination of onvansertib, the company's oral and highly selective PLK1 inhibitors, and standard of care therapies.